| Autor: |
Ishigami E; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Sakakibara M; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Sakakibara J; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Iwase T; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Hayama S; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Masuda T; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Nakagawa A; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Nagashima T; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Sangai T; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Fujimoto H; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan., Otsuka M; Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260-8670, Japan. |
| Abstrakt: |
Neoadjuvant chemotherapy (NAC) with anthracyclines followed by taxane chemotherapy has become the standard treatment for patients with locally advanced, operable breast cancer. Recently, the efficacy of nanoparticle albumin-bound paclitaxel (nab-PTX) for metastatic breast cancer was reported. However, there are still few studies of a neoadjuvant regimen including nab-PTX. Thus, the present phase II study evaluated the efficacy and safety of 5-fluorouracil, epirubicin and cyclophosphamide (FEC regimen) followed by nab-PTX as neoadjuvant treatment for operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Women with operable HER2-negative breast cancer (clinical stage T1a-4N1-3) received 4 cycles of FEC (5-fluorouracil 500 mg/m 2 , epirubicin 100 mg/m 2 and cyclophosphamide 500 mg/m 2 every 21 days), followed by 4 cycles of nab-PTX at 260 mg/m 2 every 21 days. The patients then underwent mastectomy or breast-conserving surgery (BCS). The primary endpoint was pathological complete response (pCR) rate. The secondary endpoints included clinical response rate, pathological response rate, BCS rate and safety. A total of 16 patients were evaluated and 3 patients (18%) achieved pCR (1 patient with estrogen receptor-positive cancer and 2 with estrogen receptor-negative cancer). The pCR rate was 12 and 25% in patients with estrogen receptor-positive and -negative cancers, respectively. The clinical response rate was 100% (clinical complete and partial response in 6 and 10 patients, respectively). The BCS rate was 31.25%. Three patients experienced grade 3 neutropenia during FEC therapy, and no grade 3/4 events occurred during nab-PTX therapy. Thus, neoadjuvant therapy with FEC followed by nab-PTX for operable HER2-negative breast cancer was found to be a safe and effective option. |
